CDR-Life completes fifth milestone and is recruiting patients for Phase 2 study of BI 771716
This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.
(Image credit: AdobeStock/oatawa)
CDR-Life under its collaboration and licensing agreement with Boehringer Ingelheim has completed its fifth milestone and is enrolling patients in a Phase 2 study to advance the candidate BI 771716, a novel therapeutic candidate for the treatment of geographic atrophy (GA).1
This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses. The program has advanced into Phase 2 (NCT06722157) with patient recruitment now underway.1
BI 771716, engineered using CDR-Life's proprietary technology and developed by Boehringer Ingelheim, is a unique antibody fragment design allows for enhanced penetration across retinal layers to reach key disease targets. These distinctive molecular characteristics position BI 771716 as a potentially transformative treatment for GA.1
Christian Leisner, PhD, Chief Executive Officer at CDR-Life is quoted in the company’s press release,1 saying, “The achievement of this important fifth milestone in our partnership with Boehringer Ingelheim underscores the steady progress of BI 771716 in clinical development. This milestone further reinforces the ability of our platform to deliver drug candidates with the potential to treat devasting diseases such as GA.”
CDR-Life and Boehringer Ingelheim initiated their collaboration and licensing agreement in May 2020, followed by the selection of an antibody fragment-based therapeutic candidate in September 2021. The companies have successfully executed all milestones to date.1
